Work

18 F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry

Year: 2026

Type: article

Study design: Observational Study

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.126.272588

Authors: Frank J. Borm, Jasper Smit, Nienke R. Gerards, Sanne E. Wiegers, Vincent van der Noort, Yihzi Wang, Danielle Cohen, Kim Monkhorst, Diederik J. Grootendorst, David Leung, Ronald Boellaard, Egbert F. Smit, Adrianus J. de Langen

Institutions: The Netherlands Cancer Institute, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Leiden University Medical Center, Bristol-Myers Squibb (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7224583691

FWCI:

Cites: 22

Cited by:

Related to: 10